Segui
Elisabetta Filomena Buonaguro
Elisabetta Filomena Buonaguro
Dpt Neuroscienze, Facoltà di Medicina Federico II, Napoli
Email verificata su studenti.unina.it - Home page
Titolo
Citata da
Citata da
Anno
An update of safety of clinically used atypical antipsychotics
L Orsolini, C Tomasetti, A Valchera, R Vecchiotti, I Matarazzo, F Vellante, ...
Expert opinion on drug safety 15 (10), 1329-1347, 2016
1302016
Serotonin–glutamate and serotonin–dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic …
A de Bartolomeis, EF Buonaguro, F Iasevoli
Psychopharmacology 225, 1-19, 2013
1032013
Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to …
A de Bartolomeis, R Balletta, S Giordano, EF Buonaguro, G Latte, ...
Psychiatry research 210 (2), 387-395, 2013
972013
Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: role of Homer signaling, and …
A de Bartolomeis, C Sarappa, EF Buonaguro, F Marmo, A Eramo, ...
Progress in Neuro-Psychopharmacology and Biological Psychiatry 46, 1-12, 2013
742013
Treating the synapse in major psychiatric disorders: the role of postsynaptic density network in dopamine-glutamate interplay and psychopharmacologic drugs molecular actions
C Tomasetti, F Iasevoli, EF Buonaguro, D De Berardis, M Fornaro, ...
International Journal of Molecular Sciences 18 (1), 135, 2017
642017
Affective temperaments are associated with specific clusters of symptoms and psychopathology: a cross-sectional study on bipolar disorder inpatients in acute manic, mixed, or …
F Iasevoli, A Valchera, E Di Giovambattista, M Marconi, MP Rapagnani, ...
Journal of affective disorders 151 (2), 540-550, 2013
582013
Dopamine transporter (DAT) genetic hypofunction in mice produces alterations consistent with ADHD but not schizophrenia or bipolar disorder
M Mereu, G Contarini, EF Buonaguro, G Latte, F Managò, F Iasevoli, ...
Neuropharmacology 121, 179-194, 2017
552017
The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment
F Iasevoli, C Tomasetti, E F Buonaguro, A de Bartolomeis
Current neuropharmacology 12 (3), 219-238, 2014
552014
The emerging role of dopamine–glutamate interaction and of the postsynaptic density in bipolar disorder pathophysiology: implications for treatment
A de Bartolomeis, EF Buonaguro, F Iasevoli, C Tomasetti
Journal of psychopharmacology 28 (6), 505-526, 2014
502014
Immediate-early genes modulation by antipsychotics: translational implications for a putative gateway to drug-induced long-term brain changes
A De Bartolomeis, EF Buonaguro, G Latte, R Rossi, F Marmo, F Iasevoli, ...
Frontiers in behavioral neuroscience 11, 240, 2017
462017
Imaging brain gene expression profiles by antipsychotics: region-specific action of amisulpride on postsynaptic density transcripts compared to haloperidol
A de Bartolomeis, F Marmo, EF Buonaguro, R Rossi, C Tomasetti, ...
European Neuropsychopharmacology 23 (11), 1516-1529, 2013
392013
New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine
L Orsolini, C Tomasetti, A Valchera, F Iasevoli, EF Buonaguro, F Vellante, ...
Expert Review of Neurotherapeutics 16 (5), 483-495, 2016
382016
The burden of mood-disorder/cerebrovascular disease comorbidity: essential neurobiology, psychopharmacology, and physical activity interventions
M Fornaro, M Solmi, N Veronese, D De Berardis, EF Buonaguro, ...
International Review of Psychiatry 29 (5), 425-435, 2017
372017
Lurasidone in the treatment of bipolar depression: systematic review of systematic reviews
M Fornaro, D De Berardis, G Perna, M Solmi, N Veronese, L Orsolini, ...
BioMed Research International 2017, 2017
362017
Current and future perspectives on the major depressive disorder: focus on the new multimodal antidepressant vortioxetine
L Orsolini, C Tomasetti, A Valchera, F Iasevoli, EF Buonaguro, M Fornaro, ...
CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2017
352017
Progressive recruitment of cortical and striatal regions by inducible postsynaptic density transcripts after increasing doses of antipsychotics with different receptor profiles …
A de Bartolomeis, F Iasevoli, F Marmo, EF Buonaguro, A Eramo, R Rossi, ...
European Neuropsychopharmacology 25 (4), 566-582, 2015
302015
Safety and tolerability of antipsychotic agents in neurodevelopmental disorders: a systematic review
F Iasevoli, A Barone, EF Buonaguro, L Vellucci, A de Bartolomeis
Expert Opinion on Drug Safety 19 (11), 1419-1444, 2020
202020
Re-arrangements of gene transcripts at glutamatergic synapses after prolonged treatments with antipsychotics: A putative link with synaptic remodeling
EF Buonaguro, F Iasevoli, F Marmo, A Eramo, G Latte, C Avagliano, ...
Progress in Neuro-Psychopharmacology and Biological Psychiatry 76, 29-41, 2017
202017
COVID-19 and intellectual disability/autism spectrum disorder with high and very high support needs: issues of physical and mental vulnerability
EF Buonaguro, MO Bertelli
Advances in Mental Health and Intellectual Disabilities 15 (1), 8-19, 2021
192021
Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia
F Iasevoli, EF Buonaguro, C Sarappa, F Marmo, G Latte, R Rossi, ...
Progress in Neuro-Psychopharmacology and Biological Psychiatry 54, 299-314, 2014
192014
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20